Nirogy Therapeutics is a privately held biotechnology company based in Boston developing small-molecule drugs that target cellular transporter proteins (SLCTs). The company relies on a proprietary small-molecule compound library and rapid development strategies to generate a pipeline of first-in-class medicines. Its lead program targets lactate transporters and has shown robust anti-tumor efficacy in preclinical models as monotherapy and in combination, with an anticipated entry into human clinical trials in 2022. Nirogy also has a second transporter-targeted cancer program and a third program in immunology. Management cites strengths in computational modeling, medicinal chemistry, and cancer biology as enabling the drugging of challenging SLCT targets. The company plans to use recent financing proceeds to advance its drug discovery platform and pipeline.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2021